Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of the hormonal preparation used in assisted reproduction. Myovant Sciences Ltd. has partnership with Flo Health to create a digital tool to screen for heavy menstrual bleeding. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was founded in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone44-20-3318-9709
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees86
Next Earnings Date6/6/2019 (Estimated)
OptionableNot Optionable
Myovant Sciences (NYSE:MYOV) Frequently Asked Questions
What is Myovant Sciences' stock symbol?
Myovant Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "MYOV."
How were Myovant Sciences' earnings last quarter?
Myovant Sciences Ltd (NYSE:MYOV) announced its earnings results on Thursday, February, 7th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.98) by $0.06. View Myovant Sciences' Earnings History.
When is Myovant Sciences' next earnings date?
What price target have analysts set for MYOV?
7 Wall Street analysts have issued 1 year price targets for Myovant Sciences' shares. Their predictions range from $25.00 to $42.00. On average, they expect Myovant Sciences' stock price to reach $31.20 in the next twelve months. This suggests a possible upside of 143.6% from the stock's current price. View Analyst Price Targets for Myovant Sciences.
What is the consensus analysts' recommendation for Myovant Sciences?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myovant Sciences in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Myovant Sciences.
Has Myovant Sciences been receiving favorable news coverage?
Press coverage about MYOV stock has been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Myovant Sciences earned a news sentiment score of 0.7 on InfoTrie's scale. They also gave news stories about the company a news buzz of 7.0 out of 10, indicating that recent media coverage is likely to have an effect on the company's share price in the near future.
Are investors shorting Myovant Sciences?
Myovant Sciences saw a increase in short interest in April. As of April 30th, there was short interest totalling 1,752,563 shares, an increase of 36.0% from the April 15th total of 1,289,045 shares. Based on an average daily trading volume, of 115,934 shares, the short-interest ratio is currently 15.1 days. Approximately 8.8% of the shares of the company are sold short. View Myovant Sciences' Current Options Chain.
Who are some of Myovant Sciences' key competitors?
Some companies that are related to Myovant Sciences include ACADIA Pharmaceuticals (ACAD), HUTCHISON CHINA/S (HCM), Ultragenyx Pharmaceutical (RARE), Global Blood Therapeutics (GBT), FibroGen (FGEN), Agios Pharmaceuticals (AGIO), Amicus Therapeutics (FOLD), Biohaven Pharmaceutical (BHVN), Amneal Pharmaceuticals (AMRX), Mirati Therapeutics (MRTX), Reata Pharmaceuticals (RETA), Arena Pharmaceuticals (ARNA), Intercept Pharmaceuticals (ICPT), The Medicines (MDCO) and Uniqure (QURE).
What other stocks do shareholders of Myovant Sciences own?
Who are Myovant Sciences' key executives?
Myovant Sciences' management team includes the folowing people:
- Dr. Lynn Seely, Principal Exec. Officer, Pres & Exec. Director (Age 60)
- Mr. Frank L. Karbe, Chief Financial Officer (Age 51)
- Mr. Matthew Lang, Gen. Counsel & Sec. (Age 43)
- Ms. Julie Tran MBA, MSHR, Sr. VP of HR
- Ms. Marianne L. Romeo, Head of Global Transactions & Risk Management (Age 51)
When did Myovant Sciences IPO?
(MYOV) raised $176 million in an initial public offering on Thursday, October 27th 2016. The company issued 13,000,000 shares at $12.00-$15.00 per share. Citigroup, Cowen and Company, Evercore ISI and Barclays served as the underwriters for the IPO and JMP Securities and Baird were co-managers.
Who are Myovant Sciences' major shareholders?
Myovant Sciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Janus Henderson Group PLC (3.54%), Victory Capital Management Inc. (1.19%), Emory University (0.16%), JPMorgan Chase & Co. (0.12%), Swiss National Bank (0.04%) and Wells Fargo & Company MN (0.03%). Company insiders that own Myovant Sciences stock include Ferreira Juan Camilo Arjona, Holdings Ltd Dexxon, Mark Altmeyer and Pharmaceuticals Interna Takeda. View Institutional Ownership Trends for Myovant Sciences.
Which major investors are selling Myovant Sciences stock?
Which major investors are buying Myovant Sciences stock?
MYOV stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Morgan Stanley and Swiss National Bank. Company insiders that have bought Myovant Sciences stock in the last two years include Holdings Ltd Dexxon, Mark Altmeyer and Pharmaceuticals Interna Takeda. View Insider Buying and Selling for Myovant Sciences.
How do I buy shares of Myovant Sciences?
Shares of MYOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Myovant Sciences' stock price today?
One share of MYOV stock can currently be purchased for approximately $12.81.
How big of a company is Myovant Sciences?
Myovant Sciences has a market capitalization of $907.08 million. Myovant Sciences employs 86 workers across the globe.
What is Myovant Sciences' official website?
How can I contact Myovant Sciences?
Myovant Sciences' mailing address is 11-12 ST. JAMES`S SQUARE SUITE 1 3RD FLOOR, LONDON X0, SW1Y 4LB. The company can be reached via phone at 44-20-3318-9709 or via email at [email protected]
MarketBeat Community Rating for Myovant Sciences (NYSE MYOV)
MarketBeat's community ratings are surveys of what our community members think about Myovant Sciences and other stocks. Vote "Outperform" if you believe MYOV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYOV will underperform the S&P 500 over the long term. You may vote once every thirty days.
